Atara Biotherapeutics (ATRA) Cash & Current Investments (2013 - 2026)

Atara Biotherapeutics' Cash & Current Investments history runs 14 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• Quarterly Cash & Current Investments fell 39.6% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 39.6% YoY) and the FY2025 annual result came in at $8.5 million, down 66.31% from the prior year.
• Cash & Current Investments was $8.4 million for Q1 2026 at Atara Biotherapeutics, down from $8.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $301.8 million in Q1 2022 and bottomed at $5.7 million in Q3 2025.
• A 5-year average of $65.1 million and a median of $46.2 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 128.48% — and 2025, when it plunged 87.68%.
• Atara Biotherapeutics' Cash & Current Investments stood at $242.8 million in 2022, then slumped by 78.7% to $51.7 million in 2023, then plunged by 51.33% to $25.2 million in 2024, then tumbled by 66.31% to $8.5 million in 2025, then dropped by 1.44% to $8.4 million in 2026.
• Business Quant data shows ATRA's Cash & Current Investments at $8.4 million in Q1 2026, $8.5 million in Q4 2025, and $5.7 million in Q3 2025.